Found: 16
Select item for more details and to access through your institution.
Necrobiotic Xanthogranuloma Treated With Topical Nitrogen Mustard (Mechlorethamine).
- Published in:
- 2016
- By:
- Publication type:
- journal article
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 4, p. 863, doi. 10.1007/s00277-023-05090-z
- By:
- Publication type:
- Article
Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019.
- Published in:
- European Journal of Haematology, 2021, v. 107, n. 4, p. 428, doi. 10.1111/ejh.13679
- By:
- Publication type:
- Article
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
mTOR has distinct functions in generating versus sustaining humoral immunity.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 10, p. 701, doi. 10.1016/j.clml.2021.05.017
- By:
- Publication type:
- Article
Organ Biomarker Responses in Patients With Light Chain Amyloidosis Treated With NEOD001 Are Independent of Previous Hematologic Response.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e97, doi. 10.1016/j.clml.2017.03.175
- By:
- Publication type:
- Article
NEOD001 Demonstrates Organ Biomarker Responses in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Results From a Phase 1/2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e22, doi. 10.1016/j.clml.2017.03.038
- By:
- Publication type:
- Article
Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e14, doi. 10.1016/j.clml.2017.03.025
- By:
- Publication type:
- Article
Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 12, p. E506, doi. 10.1002/ajh.24563
- By:
- Publication type:
- Article
Proteasome inhibitor associated thrombotic microangiopathy.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 9, p. E348, doi. 10.1002/ajh.24447
- By:
- Publication type:
- Article
Reappraisal of risk factors for monoclonal gammopathy of undetermined significance.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 6, p. 581, doi. 10.1002/ajh.24355
- By:
- Publication type:
- Article
Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 6, p. 475, doi. 10.1002/ajh.22025
- By:
- Publication type:
- Article
Multiple myeloma with lacrimal gland amyloidosis and sarcoidosis.
- Published in:
- American Journal of Hematology, 2010, v. 85, n. 7, p. 506, doi. 10.1002/ajh.21695
- By:
- Publication type:
- Article
The impact of race on outcomes of autologous transplantation in patients with multiple myeloma.
- Published in:
- American Journal of Hematology, 2008, v. 83, n. 5, p. 355, doi. 10.1002/ajh.21139
- By:
- Publication type:
- Article
Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 5, p. 656, doi. 10.1002/jcph.1994
- By:
- Publication type:
- Article